3/18
12:30 am
gpcr
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]
Medium
Report
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]
3/17
01:11 pm
gpcr
Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.
3/17
07:48 am
gpcr
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]
Low
Report
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]
3/16
02:12 pm
gpcr
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.
3/16
12:35 pm
gpcr
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]
Medium
Report
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]
3/16
12:23 pm
gpcr
Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.
3/16
12:08 pm
gpcr
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by Leerink Partners.
3/16
07:08 am
gpcr
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron [Yahoo! Finance]
Medium
Report
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron [Yahoo! Finance]
3/16
07:00 am
gpcr
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Medium
Report
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
3/2
08:56 am
gpcr
Structure Therapeutics (GPCR) had its price target raised by HC Wainwright from $90.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) had its price target raised by HC Wainwright from $90.00 to $114.00. They now have a "buy" rating on the stock.
2/28
01:30 am
gpcr
Low
Report
2/27
11:30 am
gpcr
Assessing Structure Therapeutics (GPCR) Valuation After Sharp Swings And A Strong 1 Year Return [Yahoo! Finance]
Neutral
Report
Assessing Structure Therapeutics (GPCR) Valuation After Sharp Swings And A Strong 1 Year Return [Yahoo! Finance]
2/27
11:21 am
gpcr
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million [Yahoo! Finance]
Low
Report
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million [Yahoo! Finance]
2/27
09:21 am
gpcr
Structure Therapeutics (GPCR) had its price target lowered by Citizens Jmp from $120.00 to $113.00. They now have a "market outperform" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) had its price target lowered by Citizens Jmp from $120.00 to $113.00. They now have a "market outperform" rating on the stock.
2/26
04:22 pm
gpcr
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights [Yahoo! Finance]
2/26
04:02 pm
gpcr
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Low
Report
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
2/25
04:14 pm
gpcr
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position [Yahoo! Finance]
Low
Report
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position [Yahoo! Finance]
2/19
07:17 am
gpcr
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data [Yahoo! Finance]
Low
Report
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data [Yahoo! Finance]
2/18
04:52 pm
gpcr
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? [Seeking Alpha]
Low
Report
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? [Seeking Alpha]
2/8
04:41 pm
gpcr
Assessing Structure Therapeutics (GPCR) Valuation As GSBR-1290 Advances Through Phase 2 Obesity Trials [Yahoo! Finance]
Medium
Report
Assessing Structure Therapeutics (GPCR) Valuation As GSBR-1290 Advances Through Phase 2 Obesity Trials [Yahoo! Finance]
2/3
01:37 pm
gpcr
Obesity stocks slump on Novo's underwhelming 2026 sales forecast [Yahoo! Finance Canada]
Low
Report
Obesity stocks slump on Novo's underwhelming 2026 sales forecast [Yahoo! Finance Canada]
1/31
03:15 pm
gpcr
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more [Seeking Alpha]
Low
Report
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more [Seeking Alpha]
1/31
01:33 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at
Wall
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at
Wall
1/24
05:10 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/23
06:57 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.